CN106170557B - 作为化疗应答标志物的微生物群组合物，以及微生物调节剂(益生元、益生菌或合生元)用于提高癌症治疗效力的用途 - Google Patents

作为化疗应答标志物的微生物群组合物，以及微生物调节剂(益生元、益生菌或合生元)用于提高癌症治疗效力的用途 Download PDF

Info

Publication number
CN106170557B
CN106170557B CN201480063481.9A CN201480063481A CN106170557B CN 106170557 B CN106170557 B CN 106170557B CN 201480063481 A CN201480063481 A CN 201480063481A CN 106170557 B CN106170557 B CN 106170557B
Authority
CN
China
Prior art keywords
ctx
cells
mice
bacteria
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480063481.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106170557A (zh
Inventor
L·齐特沃吉尔
I·贡珀茨博内卡
P·勒帕热
S·维奥
R·达耶尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Academy Of Agriculture Food And Environment
Gustavus Institute
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Sud
Original Assignee
Gustavus Institute
Institut National de la Recherche Agronomique INRA
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gustavus Institute, Institut National de la Recherche Agronomique INRA, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Sud filed Critical Gustavus Institute
Publication of CN106170557A publication Critical patent/CN106170557A/zh
Application granted granted Critical
Publication of CN106170557B publication Critical patent/CN106170557B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201480063481.9A 2013-11-21 2014-11-21 作为化疗应答标志物的微生物群组合物，以及微生物调节剂(益生元、益生菌或合生元)用于提高癌症治疗效力的用途 Active CN106170557B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306597.9 2013-11-21
EP13306597.9A EP2876167A1 (en) 2013-11-21 2013-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
PCT/IB2014/066249 WO2015075688A1 (en) 2013-11-21 2014-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment

Publications (2)

Publication Number Publication Date
CN106170557A CN106170557A (zh) 2016-11-30
CN106170557B true CN106170557B (zh) 2020-08-21

Family

ID=49680948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480063481.9A Active CN106170557B (zh) 2013-11-21 2014-11-21 作为化疗应答标志物的微生物群组合物，以及微生物调节剂(益生元、益生菌或合生元)用于提高癌症治疗效力的用途

Country Status (13)

Country Link
US (2) US10646521B2 (enExample)
EP (2) EP2876167A1 (enExample)
JP (2) JP6662775B2 (enExample)
KR (1) KR102464342B1 (enExample)
CN (1) CN106170557B (enExample)
AU (1) AU2014351348B2 (enExample)
CA (1) CA2931363C (enExample)
DK (1) DK3071709T3 (enExample)
ES (1) ES2764282T3 (enExample)
IL (2) IL245751B (enExample)
PT (1) PT3071709T (enExample)
SG (1) SG10201803877YA (enExample)
WO (1) WO2015075688A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835581C1 (ru) * 2024-07-03 2025-02-28 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Способ подбора пробиотических и аутопробиотических штаммов микроорганизмов по устойчивости к цитостатикам при терапии колоректального рака

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112016002056T5 (de) 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
KR102661603B1 (ko) * 2015-06-01 2024-04-29 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
EP3130680A1 (en) * 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
EP4592391A3 (en) 2015-10-21 2025-10-08 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
MA45287A (fr) * 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201609811D0 (en) * 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN106011281B (zh) * 2016-07-19 2019-04-23 浙江大学 肠道分节丝状菌鞭毛蛋白的检测方法
CN109715059A (zh) * 2016-09-16 2019-05-03 优比欧迈公司 用于组表征的方法和系统
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
KR102644935B1 (ko) * 2016-12-22 2024-03-07 인스티튜트 구스타브 루시 항-PD1/PD-L1/PD-L2 항체에 대한 반응성의 마커로서의 미생물총 조성물, 및 항-PD1/PD-L1/PD-L2 Ab-기반 치료의 효능을 개선하기 위한 미생물 조정제의 용도
WO2018145082A1 (en) * 2017-02-06 2018-08-09 New York University Methods and compositions for treating and diagnosing pancreatic cancers
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
MA49982A (fr) * 2017-08-10 2020-06-17 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
CN107904298A (zh) * 2017-12-29 2018-04-13 苏州普瑞森基因科技有限公司 一种用于分析肠道微生物的试剂盒及其应用
EP3505177A1 (en) * 2017-12-29 2019-07-03 Institut Gustave Roussy Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
CN111886333A (zh) * 2018-02-09 2020-11-03 学校法人庆应义塾 诱导cd8+t细胞的组合物和方法
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
KR20210040997A (ko) * 2018-08-05 2021-04-14 다 볼떼라 항암제 효능의 개선 방법
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP3629023A1 (en) * 2018-09-28 2020-04-01 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
IL311084A (en) * 2018-11-30 2024-04-01 Caris Mpi Inc New generation molecular characterization
CN113166815B (zh) * 2019-02-22 2024-06-11 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CN113906130A (zh) * 2019-03-28 2022-01-07 千实验室株式会社 粪杆菌属微生物及包含其的抗癌组合物
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
EP3965750A4 (en) * 2019-05-08 2023-07-12 Garvan Institute of Medical Research Cancer stratification and treatment based on inhibition of nod-2
KR20220116438A (ko) * 2019-11-01 2022-08-23 유티아이 리미티드 파트너쉽 암 치료를 위한 미생물총 및 대사산물의 힘 활용
WO2021102510A1 (en) * 2019-11-26 2021-06-03 South Australian Health And Medical Research Institute Limited Methods and products for reducing side effects associated with use of immune agonist antibodies
WO2021112918A1 (en) * 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
CN114832088A (zh) * 2022-05-19 2022-08-02 李臻 拉瑞唑来多肽在制备缓解阿霉素心脏毒性药物中的用途
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116287355A (zh) * 2023-05-12 2023-06-23 中国医学科学院北京协和医院 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型
CN117237952B (zh) * 2023-11-15 2024-02-09 山东大学 基于免疫地形图的染色病理切片细胞分布标注方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102215836A (zh) * 2008-09-19 2011-10-12 雀巢产品技术援助有限公司 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295631A (ja) 1995-02-27 1996-11-12 Nichinichi Seiyaku Kk 制癌増強剤
JPH1029946A (ja) * 1996-07-15 1998-02-03 Nichinichi Seiyaku Kk 液性免疫回復剤
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
CA2736774C (en) 2008-09-19 2017-08-22 Institut Curie Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
JP5717116B2 (ja) * 2008-12-22 2015-05-13 学校法人昭和大学 抗原特異的ヒトＴｈ１７細胞を調整する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102215836A (zh) * 2008-09-19 2011-10-12 雀巢产品技术援助有限公司 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study;P Osterlund et al.,;《British Journal of Cancer》;20071231;第97卷;1028-1034 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835581C1 (ru) * 2024-07-03 2025-02-28 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Способ подбора пробиотических и аутопробиотических штаммов микроорганизмов по устойчивости к цитостатикам при терапии колоректального рака

Also Published As

Publication number Publication date
CA2931363A1 (en) 2015-05-28
JP2020050664A (ja) 2020-04-02
KR102464342B1 (ko) 2022-11-08
KR20160079122A (ko) 2016-07-05
AU2014351348B2 (en) 2020-12-03
EP2876167A1 (en) 2015-05-27
US10646521B2 (en) 2020-05-12
IL245751B (en) 2019-08-29
JP6662775B2 (ja) 2020-03-11
EP3071709B1 (en) 2019-12-25
ES2764282T3 (es) 2020-06-02
US20160303172A1 (en) 2016-10-20
IL268526A (en) 2019-09-26
DK3071709T3 (da) 2020-03-16
CA2931363C (en) 2023-07-18
JP2016539119A (ja) 2016-12-15
US11344586B2 (en) 2022-05-31
PT3071709T (pt) 2020-01-17
CN106170557A (zh) 2016-11-30
IL268526B (en) 2022-02-01
SG10201803877YA (en) 2018-06-28
EP3071709A1 (en) 2016-09-28
WO2015075688A1 (en) 2015-05-28
AU2014351348A1 (en) 2016-06-09
IL245751A0 (en) 2016-07-31
US20200360449A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
US11344586B2 (en) Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
US20230263843A1 (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
AU2015334468B2 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
Roberti et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
JP7441167B2 (ja) 結腸直腸癌の治療のための細菌及び細胞組成物並びにそれを有する患者の予後を評価するための方法
US20160120915A1 (en) Methods for manipulating immune responses by altering microbiota
Zuo et al. Bifidobacterium infantis attenuates colitis by regulating T cell subset responses
US20240398876A1 (en) Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-pdi drug
EP3601614A1 (en) Method for determining the potential efficacy of anticancer treatment
KR20240093392A (ko) 질병 치료를 위한 조성물 및 방법
D'Amico The human gut microbiome in disease: Role in chemotherapy treatments and relationship with clinical outcomes
Stendel Assessing the Changes to the Gut Microbiome Following Radiation Therapy in a Bladder Cancer Context
Geis REGULATORY T CELLS PROMOTE IL-17-DEPENDENT CARCINOGENIC IMMUNITY TO ENTEROTOXIGENIC BACTEROIDES FRAGILIS
Class et al. Patent application title: METHODS FOR MANIPULATING IMMUNE RESPONSES BY ALTERING MICROBIOTA Inventors: Martin J. Blaser (New York, NY, US) Martin J. Blaser (New York, NY, US) Shingo Yamanishi (Bunkyo-Ku, JP) Laura M. Cox (Brooklyn, NY, US) Victoria E. Ruiz (Brooklyn, NY, US) Alexandra E. Livanos (New York, NY, US) Assignees: New York University
Serrano Honeyman et al. Downregulated Th17 responses are associated with reduced gastritis in Helicobacter pylori-infected children

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20191101

Address after: Fa Guobali

Applicant after: National Health and Medicine Inst.

Applicant after: Nanterre

Applicant after: National Institute of Agronomique

Address before: Fa Guoweileruifu

Applicant before: Gustavoiros Institute

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200720

Address after: Fa Guoweileruifu

Applicant after: Gustavus Institute

Applicant after: INSERM (Institut National de la Sante et de la Recherche Medicale)

Applicant after: University PARIS SUD

Applicant after: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

Address before: Fa Guobali

Applicant before: INSERM (Institut National de la Sante et de la Recherche Medicale)

Applicant before: University PARIS SUD

Applicant before: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Fa Guoweileruifu

Patentee after: Gustavus Institute

Patentee after: INSERM (Institut National de la Sante et de la Recherche Medicale)

Patentee after: University PARIS SUD

Patentee after: French National Academy of agriculture, food and environment

Address before: Fa Guoweileruifu

Patentee before: Gustavus Institute

Patentee before: INSERM (Institut National de la Sante et de la Recherche Medicale)

Patentee before: University PARIS SUD

Patentee before: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

CP01 Change in the name or title of a patent holder